Search
eCTD 4.0 Explained: FDA, EMA and Japan Deadlines, Key Changes and What It Means for Regulatory Affairs Careers
**eCTD 4.0** is the next-generation global standard for electronic pharmaceutical regulatory submissions, replacing the document-centric **eCTD 3.2.2** format used since 2008. It affects regulatory affairs professionals, publishing specialists and every company submitting dossiers to the **FDA**, **EMA**, **PMDA** and other health authorities. The **FDA** has accepted eCTD 4.0 for new applications since **16 September 2024**; **Japan** targets a mandate by **April 2026**; and
Aug 1212 min read
The European Biotech Act 2026: What the New EU Biotechnology Framework Means for Pharma, Biotech and Regulatory Affairs Careers
The **European Biotech Act** is a European Commission legislative proposal, published as **COM(2025) 1022 final on 16 December 2025**, designed to close the EU's competitiveness gap in health biotechnology against the US and China. It affects pharmaceutical companies, biotech start-ups, investors and regulatory affairs professionals working with **ATMPs**, mRNA therapeutics, biologics and biosimilars. The Act introduces faster clinical trial timelines, EU-anchored investment
Aug 1212 min read
Why 90% of Regulatory Affairs Applicants Get Zero Job Offers (And How to Be the 10%)
Most regulatory affairs applicants never get an interview. Learn why — and the specific CV, experience and training fixes that put you in the top 10%. The overwhelming majority of regulatory affairs job applications fail before a human ever reads the covering letter. This article explains what happens to those applications, who typically gets rejected, why relevant scientific and clinical experience is routinely overlooked, and what separates the small minority of candidates
Jul 3112 min read